What is Ganirelix Market Scope?
Ganirelix acetate (or diacetate), which is sold under the brand names Orgalutran and Antagon, is an injectable competitive gonadotropin-releasing hormone antagonist (GnRH antagonist). It is mainly used in assisted reproduction to control ovulation. Ganirelix is used as a drug used to treat fertility in people with ovaries. In particular, it is used to prevent premature ovulation in people with ovaries who are undergoing fertility treatment that involves overstimulation of the ovaries, causing the ovaries to produce multiple eggs. When such premature ovulation occurs, the eggs released by the ovaries may be too immature to be used for in vitro fertilization. Ganirelix hereby prevents ovulation until the period it is triggered by injecting the human chorionic gonadotropin (hCG). Ganirelix is given by the subcutaneous injection of 250 µg once daily during the mid to late follicular phase of a patient's menstrual cycle. Treatment should begin on the 5th or 6th day after the start of ovarian stimulation. The average duration of use is five days.
The Ganirelix market study is being classified, by Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment and Premature Ovarian Failure (POF)) and major geographies with country level break-up.
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Organon USA Inc. (United States), Ferring Pharmaceuticals Inc. (United States), Sun Pharmaceutical Industries Ltd. (India), Chemenu Inc. (China), Merck & Co., Inc. (United States), BLD Pharm (China), LGM Pharma (United States) and Angle Bio Pharma (India) are some of the key players profiled in the study.
Analyst at AMA have segmented the market study of Global Ganirelix market by Type, Application and Region.
On the basis of geography, the market of Ganirelix has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Influencing Market Trend
- Advancements in Infertility Treatment
- Declining Fertility Rate
- Rising Number of Fertility Clinics Worldwide
- Improving Healthcare Infrastructure in Developing Countries
- Increasing Medical Tourism
- Stringent Government Regulations
- The High Cost of Ganirelix
- Lack of Medical Infrastructure in Underdeveloped Countries
- Reduced Efficacy among Older Women
Key Target AudienceProviders of Ganirelix, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.